Unites companies from healthcare and life sciences
Velsera at a glance & key developments in 2025
Velsera is a precision medicine technology company that supports life sciences and healthcare organizations through advanced data platforms, analytics, and expert services, accelerating drug discovery, clinical development, and delivery of personalized care globally.
Velsera launched its Global Data Network (GDN) in 2025. Spanning more than 175m patient records across a global network of partners, GDN connected previously siloed datasets to accelerate drug discovery and development. By enabling faster access to high-quality, regulatory-compliant data while preserving patient privacy, the platform significantly reduced time to insight and supported more efficient, data-driven decision-making across precision medicine.
- Year acquired
- 2022
- Revenue
- EUR 27m
- Location
- Boston
- Employees
- 205
- Website
- https://www.velsera.com
- Investment theme
- Changing Demographics
- Contact
- stephanie.caspar@summaequity.com
- SDG alignment
3
What are the challenges Velsera addresses
-
73%
of advanced cancer patients may have treatment-relevant genomic findings, yet only ~8% receive genomics-matched treatment
-
93%
of clinical drug candidates fail, and each new medicine takes 10–15 years and ~$2.6B to develop
-
Who is impacted?
Velsera serves the precision-medicine ecosystem: clinical laboratories, sequencing providers, clinicians, patients, pharmaceutical companies, researchers and public research organizations. Its platforms support both clinical teams interpreting cancer genomic tests and research teams analyzing large-scale biomedical data.
-
Contribution
Velsera helps move precision medicine from data to decisions. Clinical Genomics Workspace turns complex genomic results into clinical reports used for diagnosis, prognosis, treatment selection and trial matching. Seven Bridges Platform helps researchers use health and multi-modal biomedical data at scale to accelerate discovery as well as drug and diagnostics development.
-
Risks to impact
Key risks to impact include rapidly evolving customer needs, competitive and regulatory dynamics, and challenges in scaling solutions across diverse markets in a nascent field. These factors may slow adoption and constrain the effectiveness of Velsera’s platforms in delivering impact.